Front Matter

Joan R. Asarnow, Ph.D. Dr. Asarnow has received grant funding and/or other support from the National Institute of Mental Health, the Substance Abuse and Mental Health Services Administration, the American Foundation for Suicide Prevention, the Association for Child and Adolescent Mental Health, the American Psychological Association, and the Society of Clinical Child and Adolescent Psychology. She has also served as a consultant on quality improvement interventions for depression and suicidal/self-harm behavior and on Data Safety and Monitoring and noncommercial Advisory Boards/Expert Panels, as well as on the scientific advisory board for the Klingenstein Third Generation Foundation.

Pierre Blier, M.D., Ph.D. Dr. Blier received honoraria for giving lectures and/or for participating in advisory boards and/or providing expert testimony for Allergan, Bristol Myers Squibb, Janssen, Lundbeck/Otsuka, and Pfizer. He received research grants from the Canadian Institute of Health Research, Canadian Biomarkers for Depression, and Ontario Brain Institute.

Linda L. Carpenter, M.D. Research Support: Affect Neuro (formerly Feelmore Labs), Janssen, NeoSync, Neuronetics, and Nexstim; Consultant: Janssen, Magstim, and Nexstim.

W. Edward Craighead, Ph.D. Dr. Craighead is a board member of Hugarheill ehf, an Icelandic company dedicated to the prevention of depression; receives book royalties from John Wiley & Sons (Hoboken, NJ, USA); is supported by National Institutes of Health funding, the Mary and John Brock Foundation, and the Fuqua Family Foundations; and is a consultant to the George West Mental Health Foundation, a member of the Scientific Advisory Board (SAB) of the Anxiety and Depression Association of America, and a member of the SAB for AIM for Mental Health Foundation.

Charles DeBattista, M.D. Grant Support: Abbott, Biolite, Compass, and Jansen; Consultant: Alkermes and Corcept Therapeutics.

Charles F. Gillespie, M.D., Ph.D. Consultant: Cohen Veterans Bioscience.

Benjamin Goldstein, M.D., Ph.D. Dr. Goldstein received grant or research support from the Brain and Behavior Research Foundation, Brain Canada, the Canadian Institutes of Health Research, the Heart & Stroke Foundation, the National Institute of Mental Health, the Ontario Ministry of Research & Innovation, and the University of Toronto Department of Psychiatry.

Jennifer L. Hughes, Ph.D., M.P.H. Dr. Hughes receives royalties from Guilford Press for the following book: Kennard BD, Hughes JL, Foxwell AF: CBT for Depression in Children and Adolescents: A Guide to Relapse Prevention. New York, Guilford Press, 2016. Research studies that contributed to the development of this treatment (and subsequent book) are presented in Chapter 27 of the Textbook, and this book is cited.

Ronald C. Kessler, Ph.D. In the past 3 years, Dr. Kessler received support for his epidemiological studies from Sanofi Aventis; was a consultant for Johnson & Johnson Wellness and Prevention, Sage Pharmaceuticals, Shire, and Takeda; and served on an advisory board for the Johnson & Johnson Services Inc. Lake Nona Life Project. Dr. Kessler is a co-owner of DataStat Inc., a market research firm that carries out healthcare research.

Brandon M. Kitay, M.D., Ph.D. In the last 12 months, Dr. Kitay has provided consulting services to Janssen Pharmaceuticals and has also received salary support from Janssen Pharmaceuticals and Sage Therapeutics for the conduct of research administered through Yale University and the Yale Depression Research Program. In addition, Dr. Kitay’s employer, Yale University, has a financial relationship with Janssen Pharmaceuticals, and may in the future receive financial benefits from this relationship. The University has put multiple measures in place to mitigate this institutional conflict of interest. Questions about the details of these measures should be directed to Yale University’s Conflict of Interest office.

Matthew Macaluso, D.O., DFAPA Dr. Macaluso has conducted clinical trials research as principal investigator for the following pharmaceutical companies over the last 12 months: Acadia, Allergan, AssureRx, Eisai, Lundbeck, Janssen, Naurex/Aptinyx, Neurim, and Suven. All clinical trial and study contracts were with and payments made to the Kansas University Medical Center Research Institute, a research institute affiliated with Kansas University School of Medicine–Wichita (KUSM-W).

J. John Mann, M.D. Dr. Mann receives royalties from the Research Foundation for Mental Hygiene for commercial use of the Columbia–Suicide Severity Rating Scale (C-SSRS).

John C. Markowitz, M.D. Dr. Markowitz receives minor royalties for books related to interpersonal psychotherapy from American Psychiatric Association Publishing, Basic Books, and Oxford University Press.

William V. McCall, M.D., M.S. Research Support: Merck, MECTA, and Vistagen; Scientific Advisory Board: Jazz Pharmaceuticals and Sage Therapeutics; Royalties: Wolters Kluwer Publishing; Speakers Bureau: CME Outfitters; Consultant: Anthem Insurance.

William McDonald, M.D. Dr. McDonald has research contracts from the Stanley Foundation, Soterix, Neuronetics, NeoSync, and Cervel Neurotherapeutics. He is an ad hoc member of several National Institute of Mental Health and National Institute of Neurological Disorders and Stroke study sections. He is a member of the American Psychiatric Association Council on Research and Quality representing Electroconvulsive and Neuromodulation Therapies. Dr. McDonald is compensated as the chair of the Data and Safety Monitoring Board for the National Institute on Aging multicenter study. He receives royalties from Oxford University Press from co-editing a book on the Clinical Guide to Transcranial Magnetic Stimulation in the Treatment of Depression. He is a paid consultant for Signant Health. He holds an endowed chair funded by the JB Fuqua Foundation. He is an employee of Emory University School of Medicine.

David J. Miklowitz, Ph.D. Dr. Miklowitz has received research funding from the National Institute of Mental Health (grants MH093676, MH097007, and MH117200) and from the Deutsch and Kayne Family Foundations, AIM for Mental Health, the Attias Foundation, the Danny Alberts Foundation, and the Max Gray Foundation.

Charles B. Nemeroff, M.D., Ph.D. Research Grants: National Institutes of Health (NIH), Stanley Medical Research Institute; Consultant: Bracket (Clintara), Fortress Biotech, Gerson Lehrman Group (GLG) Healthcare and Biomedical Council, Janssen Research and Development LLC, Magstim Inc, Prismic Pharmaceuticals, Sumitomo Dainippon Pharma, Sunovion Pharmaceuticals Inc, Taisho Pharmaceutical Inc, Takeda, Total Pain Solutions (TPS), and Xhale; Stock Holdings: Abbvie, OPKO Health Inc, Antares, Bracket Intermediate Holding Corp, Celgene, Network Life Sciences Inc, Seattle Genetics, and Xhale; Scientific Advisory Board: American Foundation for Suicide Prevention (AFSP), Anxiety Disorders Association of America (ADAA), Bracket (Clintara), Brain and Behavior Research Foundation (BBRF) (formerly named National Alliance for Research on Schizophrenia and Depression [NARSAD]), Laureate Institute for Brain Research Inc, RiverMend Health LLC, Skyland Trail, and Xhale; Board of Directors: ADAA, AFSP, and Gratitude America; Income or Equity ($10,000 or more): American Psychiatric Publishing, Bracket (Clintara), CME Outfitters, Takeda, and Xhale; Patents: U.S. 6,375,990B1 (method and devices for transdermal delivery of lithium) and U.S. 7,148,027B2 (method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay).

D. Jeffrey Newport, M.D., M.S. Dr. Newport has received research support from Eli Lilly, Glaxo Smith Kline (GSK), Janssen, the National Alliance for Research on Schizophrenia and Depression, the National Institutes of Health, Takeda Pharmaceuticals, and Wyeth. He has served on speakers' bureaus and/or received honoraria from AstraZeneca, Eli Lilly, GSK, Pfizer, and Wyeth. He has served on advisory boards for GSK, Janssen, and Sage Therapeutics. He has never served as a consultant to any biomedical or pharmaceutical corporations. Neither he nor his family members have ever held equity positions in biomedical or pharmaceutical corporations.

Andrew A. Nierenberg, M.D. Consulting: Acadia Pharm, Eisai, Ginger, Merck, Myriad, and Protogenics; Scientific Advisory Board: Alkermes, Jazz Pharma, Neuronetics, Otsuka, and Sage Pharma; Honoraria: Sunovion and Neurostar.

Edward Nunes, M.D. Dr. Nunes has received grant funding from the National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism.

Carmine Pariante, M.D., Ph.D., FRCPsych Prof. Pariante has received research funding from Johnson & Johnson as part of a program of research on depression and inflammation, and research funding from the Medical Research Council (U.K.) and the Wellcome Trust for research on depression and inflammation as part of two large consortia that also include Johnson & Johnson, Glaxo Smith Kline, and H. Lundbeck.

Gerard Sanacora, M.D., Ph.D. In the last 12 months Dr. Sanacora has provided consulting services to Allergan, Axsome Therapeutics, Biohaven Pharmaceuticals, Boehringer Ingelheim International, Bristol-Myers Squibb, Celexio Biosciences, EMA Wellness, Epiodyne, Intra-Cellular Therapies, Janssen, Lundbeck, Minerva Pharmaceuticals, Navitor Pharmaceuticals, Neurocrine Biosciences, NeuroRx, Noven Pharmaceuticals, Otsuka, Perception Neuroscience, Praxis, Seelos Pharmaceuticals, and Vistagen Therapeutics. He has received funds for contracted research from Janssen Pharmaceuticals, Merck, and Usona Institute. He is holds equity in Biohaven Pharmaceuticals and has received royalties from Yale University paid from patent licenses with Biohaven Pharmaceuticals. In addition, he holds shares in Biohaven Pharmaceuticals Holding Company and is a co-inventor on a patent, “Glutamate agents in the treatment of mental disorders” (Patent number: 8778979), and a U.S. Provisional Patent Application (No. 047162-7177P1 [00754]) filed on August 20, 2018, by Yale University Office of Cooperative Research (OCR 7451 US01). Dr. Sanacora’s employer, Yale University, has a financial relationship with Janssen Pharmaceuticals, and may in the future receive financial benefits from this relationship. The University has put multiple measures in place to mitigate this institutional conflict of interest. Questions about the details of these measures should be directed to Yale University’s Conflict of Interest office.

Richard C. Shelton, M.D. Dr. Shelton’s institution has received grant support from Acadia Pharmaceuticals, Agency for Healthcare Research and Quality, Alkermes, Allergan, Avanir Pharmaceuticals, Cerecor, Genomind, Intracellular Therapies, Janssen Pharmaceutica, Myriad Genetics, National Institute of Mental Health, Navitor Pharmaceuticals, NeuroRx, Novartis, Otsuka Pharmaceuticals, Patient-Centered Outcomes Research Institute, Sage Therapeutics, and Takeda Pharmaceuticals. Dr. Shelton has served as a consultant to Acadia Pharmaceuticals, Allergan, Cerecor, Janssen Pharmaceutica, MSI Methylation Sciences, Naurex, and Takeda Pharmaceuticals.

Manpreet K. Singh, M.D., M.S. Dr. Singh receives research support from Stanford’s Maternal Child Health Research Institute and Department of Psychiatry, the National Institute of Mental Health, the National Institute on Aging, Johnson & Johnson, Allergan, PCori, and the Brain and Behavior Foundation. She is on the advisory board for Sunovion and is a consultant for Google X and Limbix.

David C. Steffens, M.D., M.H.S. Consultant: Janssen Research and Development.

Michael E. Thase, M.D. Dr. Thase reports the following relationships over the past 3 years: Advisor/Consultant: Acadia, Akili, Alkermes, Allergan (Forest, Naurex), Axsome Therapeutics, Boehringer-Ingelheim, Calla, Clexio Biosciences, H. Lundbeck, Jazz Pharmaceuticals, Janssen (Johnson & Johnson), Otsuka, Perception Neuroscience, Sage Therapeutics, Seelos Pharmaceuticals, and Takeda; Grant Support: Acadia, Allergan (Forest, Naurex), Axsome Therapeutics, Intracellular, Janssen Pharmaceutica (Johnson & Johnson), Myriad (Assurex), Otsuka, and Takeda; Royalties: American Psychiatric Association Publishing, Guilford Publications, Herald House, and W.W. Norton. Spouse’s Employment: Peloton Advantage, which does business with a number of pharmaceutical companies. Disclosure of Intellectual Conflicts of Interest (all prior to 2012): paid consultant to Depression Guideline Panel, Agency for Health Care Policy and Research; unpaid consultant to Canadian Mood and Anxiety Treatment Guidelines (1st & 2nd Editions) and American Psychiatric Association (DSM-III-R, DSM-IV, and DSM-5); unpaid Work Group member, American Psychiatric Association Practice Guideline for Treatment of Patients With Bipolar Disorder (2nd Edition and, from 2006–2010, work in preparation of 3rd Edition) and American Psychiatric Association Practice Guideline for Treatment of Patients with Major Depressive Disorder (3rd Edition).

Martha C. Tompson, Ph.D. Dr. Tompson received research support from the National Institute of Mental Health, the Patient Centered Outcomes Research Institute, and the Smith Family Foundation; book royalties from Guilford Press and BVT Publishing; and honoraria from the American Psychological Association.

Lakshmi N. Yatham, M.B.B.S., FRCPC Dr. Yatham has received research grants from or has been a consultant or on speaker / advisory boards for Allergan, AstraZeneca, Alkermes, Bristol Myers Squibb, Canadian Institutes of Health Research, Canadian Network for Mood and Anxiety Treatments, Dainippon Sumitomo, Eli Lilly, Forrest, Glaxo Smith Kline, Janssen, Lundbeck, Michael Smith Foundation for Health Research, Novartis, Otsuka, Pfizer, Ranbaxy, Servier, Sunovion, Teva, the Stanley Foundation, and Valeant Pharmaceuticals.